Explore Gland Pharma’s ₹6.29 crore GST dispute from Telangana authorities over export reclassifications and credit notes for FY 2019-20. The company deems it unjustified and plans an appeal, assuring no major impact. Dive into company overview, market reactions, stock performance, and broader pharma sector implications as of March 9, 2026. Solid fundamentals persist amid short-term volatility.
Introduction
In the dynamic world of India’s pharmaceutical sector, tax disputes under the Goods and Services Tax (GST) regime are not uncommon, often arising from interpretations of export transactions and credit adjustments. Gland Pharma Limited, a Hyderabad-based leader in generic injectables, recently made headlines after receiving a GST demand notice. This blog explores the details of the case, the company’s stance, and its potential implications, drawing from the latest updates as of March 9, 2026.
Company Overview
Gland Pharma, established in 1978, specializes in complex injectables, including oncology and peptide products. With a global presence in over 60 countries and manufacturing facilities compliant with US FDA and EU GMP standards, the company has seen robust growth. In Q3 FY26 (ended December 31, 2025), it reported a 22% year-on-year revenue increase to ₹16,954 million, driven by strong demand in the US and Europe. The acquisition of Cenexi has further bolstered its European operations, contributing €50 million in Q3 revenue—a 39% jump.
The GST Demand Details
On March 5, 2026, the Deputy Commissioner (ST)-V of the GST Department in Telangana issued an order to Gland Pharma for the financial year 2019-20. The demand totals approximately ₹6.29 crore, broken down as follows:
Tax: ₹5,03,51,468
Penalty: ₹1,25,87,867
Plus applicable interest
The issues stem from:
Reclassification of ₹4,57,79,447 in export turnover as domestic sales, attracting GST.
Discrepancies in credit notes for ₹45,72,022 related to exports, possibly due to inadequate documentation or adjustments for returns and discounts.
This order was received via email on March 6, 2026, and disclosed promptly under SEBI regulations.
Such disputes highlight ongoing challenges in GST compliance for export-oriented firms, where zero-rated supplies require stringent proof to avoid tax liabilities.
Company’s Response and Outlook
Gland Pharma has described the demand as “unjustified” based on its review of facts and laws. The company intends to file an appeal with the appellate authority, expressing confidence in a positive outcome. It has emphasized that the matter poses no material risk to its financials, operations, or activities.
This isn’t isolated; similar GST notices have affected peers like GlaxoSmithKline. Gland Pharma’s strong balance sheet evident from its Q3 profit surge provides resilience. For FY26, it anticipates capex of ₹2,500 million for its base business and €25 million for Cenexi.
Market Reaction and Stock Performance
The announcement led to a dip in Gland Pharma’s shares. On March 6, 2026, the stock closed at ₹1,669, down 2.19%. By midday on the same day, it was quoting at ₹1,676.60, reflecting a 1.75% decline amid a broader Nifty Pharma index drop. Over the past month, shares have eased by about 11%, though the one-year performance shows a 28.86% tumble against Nifty’s 9.07% gain.
Social media buzz on X (formerly Twitter) echoes the news, with posts from stock trackers highlighting the appeal plans and minimal impact.
Broader Implications for the Pharma Sector
GST disputes like this underscore the need for clearer guidelines on export taxation, especially as India’s pharma exports grow. With recent GST Council decisions reducing rates on cancer drugs to 5%, the sector is adapting to a more patient-friendly regime. For Gland Pharma, this could be a minor hurdle in an otherwise upward trajectory, bolstered by USFDA approvals and expansion.
Investors should monitor the appeal’s progress and upcoming Q4 results. While short-term volatility persists, the company’s fundamentals remain solid.
Disclaimer: This is not investment advice. Consult professionals for financial decisions. Market data as of March 9, 2026.
On April 2,2026 NMC issued a fresh advisory specifically cautioning students and parents against seeking admission to several medical institutes in Uzbekistan. The Commission has flagged serious violations of the Foreign Medical Graduate Licentiate (FMGL) Regulations 2021, putting thousands of aspiring doctors at risk of having their degrees unrecognized in India.
In the fast paced world of Indian pharmaceuticals, leadership changes can signal big shifts in strategy and growth. Today, Cipla Limited one of India’s most respected drugmakers officially entered a new chapter. Following a Board meeting on March 30, 2026 company announced that long time Managing Director and Global CEO Umang Vohra has stepped down effective April 1, 2026.
India’s medical education is expanding rapidly as the National Medical Commission approves 265 new medical colleges out of 443 applications in just five years with 43 colleges cleared for 2025–26 alone, this growth boosts MBBS seats improves doctor patient ratios and creates new opportunities for NEET aspirants while strengthening healthcare in rural India.
